CU22921A1 - Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales - Google Patents

Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales

Info

Publication number
CU22921A1
CU22921A1 CU1999196A CU1999196A CU22921A1 CU 22921 A1 CU22921 A1 CU 22921A1 CU 1999196 A CU1999196 A CU 1999196A CU 1999196 A CU1999196 A CU 1999196A CU 22921 A1 CU22921 A1 CU 22921A1
Authority
CU
Cuba
Prior art keywords
murine
antibody
ior
diagnosis
recombinant antibodies
Prior art date
Application number
CU1999196A
Other languages
English (en)
Inventor
Zuzarte Mayra Ramos
Calzado Enrique Regifo
Porto Marta Duenas
De Acosta Del Rio Cristina Maria Mateo
Avila Marta Ayala
Navarro Lourdes Tatiana Roque
Garcia Hanssel Bell
Morales Alejo Antonio Morales
Escobar Normando Enrique Iznaga
Cowley Jorge Victor Gavilondo
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU1999196A priority Critical patent/CU22921A1/es
Priority to ARP000105994A priority patent/AR026463A1/es
Priority to EA200100782A priority patent/EA005169B1/ru
Priority to PCT/CU2000/000004 priority patent/WO2001036485A2/es
Priority to MXPA01007261A priority patent/MXPA01007261A/es
Priority to JP2001538974A priority patent/JP2003514831A/ja
Priority to CA002359577A priority patent/CA2359577A1/en
Priority to BR0007827-1A priority patent/BR0007827A/pt
Priority to CNB008039542A priority patent/CN1230446C/zh
Priority to CO00087150A priority patent/CO5280154A1/es
Priority to EP00977398A priority patent/EP1174441A2/en
Priority to KR1020017008965A priority patent/KR100827627B1/ko
Priority to AU15130/01A priority patent/AU783622B2/en
Priority to US09/889,480 priority patent/US6891023B1/en
Priority to TW089126622A priority patent/TWI233440B/zh
Priority to ZA200105803A priority patent/ZA200105803B/en
Publication of CU22921A1 publication Critical patent/CU22921A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con la obtención de nuevos anticuerpos recombinantes a partir del anticuerpo murino ior C5 producido por el hibridoma depositado según el tratado de Budapest bajo el número ECCC 97061101. dichos anticuerpos recombinantes se obtuvieron mediante el empleo de la tecnología del ADN recombinante, y están caracterizados por su reconocimiento al antígeno denominado ior C2. los anticuerpos recombinantes son específicamente, el anticuerpo quimérico, el anticuerpo humanizado y el fragmento tipo Fv de cadena sencilla. El anticuerpo quimérico contiene los dominios variables de la inmunoglobulina murina y las regiones constante de la inmunoglobulina humana. El anticuerpo humanizado, contiene las regiones constante de la inmunoglobulina humana y ha sido modificado específicamente en la región de los marcos (FRs) murinos y dentro de estos en aquellas zonas que pudieran resultar en un sitio antigénico para las células T. El fragmento Fv contiene los dominios variables de la inmunoglobulina murina. La presente invención además se relaciona con el uso de los anticuerpos recombinantes derivados del anticuerpo murino ior C5 para el diagnóstico y terapia de tumores colorrectales, sus metástasis y recidivas. Para ello la presente invención proporciona una composición que contiene anticuerpos monoclonales reducidos que reconocen el antígeno ior C2 y un ligando débil, el MDP con el agente reductor Sn2+ para realizar el radiomarcaje del anticuerpo con Tc-99m, Re-186, R-188 y sus similares, útil para el diagnóstico por inmunogammagrafía y radioinmunoterapia de tumores colorrectales, metástasis y recidivas.
CU1999196A 1999-11-16 1999-11-16 Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales CU22921A1 (es)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CU1999196A CU22921A1 (es) 1999-11-16 1999-11-16 Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
ARP000105994A AR026463A1 (es) 1999-11-16 2000-11-14 ANTICUERPOS Y FRAGMENTOS Fv QUE RECONOCEN EL ANTIGENO ior C2
EA200100782A EA005169B1 (ru) 1999-11-16 2000-11-16 РЕКОМБИНАНТНОЕ АНТИТЕЛО, ВЗАИМОДЕЙСТВУЮЩЕЕ С АНТИГЕННЫМ КОМПЛЕКСОМ IOR C2, Fv- ФРАГМЕНТ УКАЗАННОГО АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
PCT/CU2000/000004 WO2001036485A2 (es) 1999-11-16 2000-11-16 Anticuerpo monocolonal recombinante que reconoce el antigeno ior c2 su uso para el diagnostico y tratamiento de tumores colorectales
MXPA01007261A MXPA01007261A (es) 1999-11-16 2000-11-16 Anticuerpos y fragmentos fv que reconocen el antigeno ior c2.
JP2001538974A JP2003514831A (ja) 1999-11-16 2000-11-16 抗原ＩＯＲＣ２を認識する抗体およびＦｖフラグメント
CA002359577A CA2359577A1 (en) 1999-11-16 2000-11-16 Antibodies and fv fragment recognizing antigen ior c2
BR0007827-1A BR0007827A (pt) 1999-11-16 2000-11-16 Anticorpos e fragmento fv que reconhecemantìgeno ior c2
CNB008039542A CN1230446C (zh) 1999-11-16 2000-11-16 识别抗原ior c2的抗体和fv片段
CO00087150A CO5280154A1 (es) 1999-11-16 2000-11-16 Anticuerpos y fragmento fv que reconocen el antigeno ior c2
EP00977398A EP1174441A2 (en) 1999-11-16 2000-11-16 Antibodies and fv fragment recognizing antigen ior c2
KR1020017008965A KR100827627B1 (ko) 1999-11-16 2000-11-16 항원 아이오알 시2를 인식하는 항체 및 에프브이 단편
AU15130/01A AU783622B2 (en) 1999-11-16 2000-11-16 Antibodies and FV fragment recognizing antigen IOR C2
US09/889,480 US6891023B1 (en) 1999-11-16 2000-11-16 Antibodies and Fv fragment recognizing antigen IOR C2
TW089126622A TWI233440B (en) 1999-11-16 2001-01-30 Antibodies and FV fragment that recognise IOR C2 antigen
ZA200105803A ZA200105803B (en) 1999-11-16 2001-07-13 Antibodies and FV fragment recognizing antigen IOR C2.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1999196A CU22921A1 (es) 1999-11-16 1999-11-16 Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales

Publications (1)

Publication Number Publication Date
CU22921A1 true CU22921A1 (es) 2004-02-20

Family

ID=5459527

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1999196A CU22921A1 (es) 1999-11-16 1999-11-16 Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales

Country Status (16)

Country Link
US (1) US6891023B1 (es)
EP (1) EP1174441A2 (es)
JP (1) JP2003514831A (es)
KR (1) KR100827627B1 (es)
CN (1) CN1230446C (es)
AR (1) AR026463A1 (es)
AU (1) AU783622B2 (es)
BR (1) BR0007827A (es)
CA (1) CA2359577A1 (es)
CO (1) CO5280154A1 (es)
CU (1) CU22921A1 (es)
EA (1) EA005169B1 (es)
MX (1) MXPA01007261A (es)
TW (1) TWI233440B (es)
WO (1) WO2001036485A2 (es)
ZA (1) ZA200105803B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
CN101389760A (zh) * 2006-02-28 2009-03-18 尼莫克斯股份有限公司 有效治疗肿瘤或其他需要除去或破坏细胞的病症的肽
CN103492852B (zh) * 2011-04-28 2016-08-17 独立行政法人理化学研究所 生物材料的透明化方法、及其利用
EP2711682B1 (en) 2011-05-20 2019-07-10 Riken Clarifying reagent for biological materials and use thereof
JP6433901B2 (ja) 2013-08-14 2018-12-05 国立研究開発法人理化学研究所 光透過性に優れた生物材料を調製するための組成物およびその利用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
EP0885404B1 (en) 1996-03-07 2001-05-02 Agfa-Gevaert N.V. Apparatus for the processing of photographic sheet material
CU22640A1 (es) * 1996-03-12 2000-12-22 Centro Inmunologia Molecular Composición farmacéutica y kit que contienen anticuerpos monoclonales para marcaje con isótopos radioactivos. sus usos para el diagnóstico y tratamiento de tumores colorrectales, sus metástasis y recidivas

Also Published As

Publication number Publication date
BR0007827A (pt) 2001-10-30
ZA200105803B (en) 2003-01-06
EP1174441A2 (en) 2002-01-23
AU1513001A (en) 2001-05-30
EA005169B1 (ru) 2004-12-30
CO5280154A1 (es) 2003-05-30
EA200100782A1 (ru) 2002-02-28
KR100827627B1 (ko) 2008-05-07
CA2359577A1 (en) 2001-05-25
WO2001036485A3 (es) 2001-11-08
US6891023B1 (en) 2005-05-10
JP2003514831A (ja) 2003-04-22
AU783622B2 (en) 2005-11-17
TWI233440B (en) 2005-06-01
CN1230446C (zh) 2005-12-07
MXPA01007261A (es) 2002-06-04
WO2001036485A2 (es) 2001-05-25
AR026463A1 (es) 2003-02-12
KR20020008113A (ko) 2002-01-29
CN1344276A (zh) 2002-04-10

Similar Documents

Publication Publication Date Title
Schultes et al. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43. 13 (Ab1)
EA200301098A1 (ru) Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей
Jan Fagerberg et al. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A
MX9504802A (es) Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
PE20050422A1 (es) Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3
DK164510C (da) Humant hybridom, humant monoklonalt antistof opnaaet derfra, anvendelse af et saadant antistof og fremgangsmaade til fremstilling af et saadant antistof
NO933179L (no) Anti-idiotype antistoffer overfor human melanoma-assosiert proteoglykanantigen
MX9201016A (es) Anticuerpos monoclonales humanizados y quimericos
ES2116789T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y empleo.
Abe et al. Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies
US6794494B1 (en) Cancerous disease modifying antibodies
PT90582A (pt) Anti-idiotype antibodies to anti-human high molecular weight-melanoma associated antigen
US20050027106A1 (en) Cancerous disease modifying antibodies
Kusama et al. Syngeneic antiidiotypic antisera to murine antihuman high-molecular-weight melanoma-associated antigen monoclonal antibodies
AR026463A1 (es) ANTICUERPOS Y FRAGMENTOS Fv QUE RECONOCEN EL ANTIGENO ior C2
Saito et al. Establishment of internal-image anti-idiotype monoclonal antibodies to a human antibody to lung cancer
Abe et al. Novel immunization protocol and ELISA screening methods used to obtain and characterize monoclonal antibodies specific for human light chain variable-region subgroups
KR930019820A (ko) 모노클로날 항-강글리오사이드 항체, 이의 제조방법 및 종양 치료제로서의 용도
ATE132906T1 (de) Neuartige antiidiotypische monoklonale antikörper
AU2007222843A1 (en) Cancerous disease modifying antibodies for diagnostic and therapeutic use in breast and ovarian cancer
CY1107163T1 (el) Συνδεδεμενα με γαγγλιοζιτη ανασυνδυασμενα αντισωματα και η χρησιμοποιηση αυτων στη διαγνωση και θεραπευτικη αγωγη ογκων
Xiang et al. Production and characterization of a tumor-specific monoclonal antibody ACT19 recognizing an epitope distinctive from sialosyl-Tn on the TAG72 antigen
Reinsberg et al. Are human anti-idiotypic anti-OC125 antibodies formed after immunization with the anti-CA125 antibody B43. 13?
AU2007222842A1 (en) Cancerous disease modifying antibodies for diagnostic and therapeutic use in breast and prostate cancer
AU2006346988A1 (en) Cancerous disease modifying antibodies